Human epididymis protein 4 as a predictor of response to neoadjuvant chemotherapy in epithelial ovarian cancer

被引：0
|
作者：
Planjery, S. [1 ]
Mohammed, O. [1 ]
Boppana, M. [1 ]
Thota, N. K. [2 ]
Ravella, V. R. [1 ]
机构：
[1] KIMS Krishna Inst Med Sci KIMS Hosp, Med Oncol, Secunderabad, India
[2] KIMS Krishna Inst Med Sci KIMS Hosp, Hematol & Med Oncol Dept, Secunderabad, India
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.228
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
192P
引用
收藏
页码：S1510 / S1510
页数：1
相关论文
共 50 条
  • [41] HUMAN EPIDIDYMIS PROTEIN 4 AS BIOMARKER FOR THE DIFFERENTIATION BETWEEN PRIMARY OVARIAN CANCER AND OVARIAN METASTASES
    Boldingh, Q. J. J.
    Stiekema, A.
    Lok, C. A. R.
    Boot, H.
    van Driel, W. J.
    Kenter, G. G.
    Korse, C. M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 280 - 281
  • [42] Human epididymis protein 4: a novel predictor of ischemic cardiomyopathy
    Tang, Yi
    Wang, Yinzhen
    Xu, Xiaoping
    Tu, Laura Yan
    Huang, Pei
    Yang, Xiaoyan
    Li, Lihua
    Wu, Juan
    Zhang, Yan
    Fu, Qinghua
    Yu, Yingli
    Zheng, Zhaofen
    Song, Lixia
    Zhang, Yi
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [43] Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer
    Wang, Min
    Hu, Ting
    Xie, Ke-Yu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2019, 12 (05): : 1723 - 1730
  • [44] Predicting response to neoadjuvant chemotherapy (NAC) in epithelial ovarian carcinoma (EOC).
    Montes, A.
    Okera, M.
    Ayis, S.
    Natas, S.
    Jacques, A.
    Winship, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Human epididymis protein 4: a novel predictor of ischemic cardiomyopathy
    Yi Tang
    Yinzhen Wang
    Xiaoping Xu
    Laura Yan Tu
    Pei Huang
    Xiaoyan Yang
    Lihua Li
    Juan Wu
    Yan Zhang
    Qinghua Fu
    Yingli Yu
    Zhaofen Zheng
    Lixia Song
    Yi Zhang
    BMC Cardiovascular Disorders, 21
  • [46] KELIM DURING NEOADJUVANT CHEMOTHERAPY AS PREDICTOR OF INTERVAL DEBULKING SURGERY AND TREATMENT RESPONSE IN ADVANCED OVARIAN CANCER
    Sepulveda, Zara Vidales
    Marin-Jimenez, Juan A.
    Ortiz, Irene
    Fernandez, Sergi
    Ortega, Carlos
    Torrejon, Carlos
    Piulats, Jose Maria
    Marti, Lola
    Gil-Martin, Marta
    Pardo, Beatriz
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A325 - A325
  • [47] CA 125 as predictor of response to chemotherapy in ovarian cancer
    Verheijen, RHM
    Van Kamp, GJ
    Kenemans, P
    7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 21 - 27
  • [48] Human Epididymis Protein 4 (HE4). A tumor marker in the diagnosis of ovarian cancer
    Zulauf, N.
    Bendels, M. H.
    Bauer, J.
    Braun, M.
    Volante, G.
    Oremek, G. M.
    Groneberg, D. A.
    Brueggmann, D.
    ZENTRALBLATT FUR ARBEITSMEDIZIN ARBEITSSCHUTZ UND ERGONOMIE, 2019, 69 (01): : 30 - 32
  • [49] Human epididymis secretory protein 4 in serum (HE4) as a marker of ovarian cancer
    Qu, K. Z.
    Li, H.
    Whitmire, R.
    Sferruzza, A.
    Bender, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Human epididymis protein 4 increases specificity for the detection of invasiive epithelial ovarian cancer in premenopausal women presenting with an adnexal mass
    Holcomb, K.
    Miller, C.
    Vucetic, Z.
    Knapp, R.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S69 - S70
12345